iRadimed Affirms FY2026 GAAP EPS Guidance of $1.90-$2.05 vs $1.91 Est

Benzinga Newsdesk www.benzinga.com Positive 63.6%

Neg 0% Neu 0% Pos 63.6%

iRadimed (NASDAQ:IRMD) affirms FY2026 GAAP EPS guidance from $1.90-$2.05 to $1.90-$2.05 vs $1.91 analyst estimate..

Comments

No comments yet. Be the first!